Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.7.0.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 12 Months Ended
Oct. 16, 2012
May 31, 2017
May 31, 2016
May 31, 2015
Commitments and Contingencies [Line Items]        
Asset purchase, cash paid $ 3,500,000      
Asset Purchase Agreement Aggregate Consideration Paying Period     10 years  
Payment to acquire other assets     $ 1,500,000  
Accrued milestone payments       $ 2,500,000
Milestone Payments        
Commitments and Contingencies [Line Items]        
Royalty on every net sales     5.00%  
Development Milestone Payments        
Commitments and Contingencies [Line Items]        
Asset Purchase Agreement Aggregate Consideration Paying Period     10 years  
Payment to acquire other assets     $ 1,000,000  
Minimum annual license maintenance fees     150,000  
Project Work Order | Termination of Any One Clinical Trial | Minimum        
Commitments and Contingencies [Line Items]        
Financial penalties   $ 100,000    
Project Work Order | Termination of Any One Clinical Trial | Maximum        
Commitments and Contingencies [Line Items]        
Financial penalties   500,000    
Project Work Order | Termination of All Clinical Trials | Minimum        
Commitments and Contingencies [Line Items]        
Financial penalties   500,000    
Project Work Order | Termination of All Clinical Trials | Maximum        
Commitments and Contingencies [Line Items]        
Financial penalties   1,800,000    
Commercial Manufacturing Companies        
Commitments and Contingencies [Line Items]        
Execution fees for process validation and manufacturing activities   2,100,000    
Commercial Manufacturing Companies | Termination of Any One Clinical Trial | Minimum        
Commitments and Contingencies [Line Items]        
Financial penalties   1,200,000    
Commercial Manufacturing Companies | Termination of Any One Clinical Trial | Maximum        
Commitments and Contingencies [Line Items]        
Financial penalties   $ 3,600,000    
First dosing in a U.S. Phase 3 trial or non-US equivalent | Milestone Payments        
Commitments and Contingencies [Line Items]        
Potential future milestone and royalties payments     1,500,000  
First dosing in a U.S. Phase 3 trial or non-US equivalent | Development Milestone Payments        
Commitments and Contingencies [Line Items]        
Potential future milestone and royalties payments     1,000,000  
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments        
Commitments and Contingencies [Line Items]        
Potential future milestone and royalties payments     5,000,000  
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Development Milestone Payments        
Commitments and Contingencies [Line Items]        
Potential future milestone and royalties payments     500,000  
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments        
Commitments and Contingencies [Line Items]        
Potential future milestone and royalties payments     $ 500,000  
Royalty on every net sales     7.50%